Coronavirus Outbreak

CSIR Sanctions Project To Develop Human Monoclonal Antibodies As Therapy For COVID-19

The project being led by Bharat Biotech aims at alternate therapeutic regimen by generating highly effective and specific human monoclonal antibodies that are capable of neutralising the SARS-CoV2 virus



  • COVID-19 vaccination alone may not provide complete solution: Dr Ella
  • We feel monoclonal antibody therapy will provide a viable option: Dr Ella
  • Bharat Biotech is trying to make antibodies available within next 6 months

Hyderabad: The Council of Scientific and Industrial Research (CSIR), under its flagship New Millennium Indian Technology Leadership Initiative programme (NMITLI), has sanctioned a project to develop human monoclonal antibodies as therapy for COVID-19 infection. The project, which is being led by leading vaccines and bio-therapeutics manufacturer Bharat Biotech, aims at alternate therapeutic regimen by generating highly effective and specific human monoclonal antibodies that are capable of neutralising the SARS-CoV2 virus.

It brings together academia – National Centre for Cell Science (NCCS), Pune and Indian Institute of Technology, Indore and industry – PredOmix Technologies, Gurgaon and Bharat Biotech in a collaborative mode for a public health emergency.

Also Read: Coronavirus Explained: All You Need To Know About The SARS Epidemic Of 2002

The purpose of vaccination is to protect the healthy against future infections and it alone may not provide the complete solution. We feel the monoclonal antibody therapy will provide a viable option, Bharat Biotech Chairman and Managing Director Dr Krishna Ella said.

Although efforts are underway for the development of drugs and vaccines for controlling the COVID-19 pandemic, these are slow and expensive processes with uncertainties. Therefore, an alternate therapeutic regimen for early deployment is critical.

The question is of how to treat those individuals who are already infected? Plus, we do not yet know how effective an anti-SARS-CoV2 vaccine will be in the elderly people and those with co-morbidities. Given the large number of Indians suffering from hypertension, diabetes, and heart diseases, this becomes an important issue, Dr Ella said.

Also Read: ‘Of Course, We Will Share It With The World’: Israel’s Ambassador To India On COVID-19 Breakthrough

Talking about the novel antibodies approach to deal with COVID19 Pandemic, Dr Ella said that while both Israel and the Netherlands have recently announced the development of virus-neutralizing antibodies, our approach is to develop a powerful cocktail of neutralizing antibodies that can also simultaneously block mutational variants of the virus.

We are fast-tracking the development process, to make the antibodies available within the next six months and thus improve the treatment efficacy, he added.

Also Read: We Need A Plan To Ensure 100 Percent Coverage For The COVID-19 Vaccine, Experts Speak

Such virus-neutralizing antibodies can block the spread of infection by binding to the virus and rendering it ineffective. Monoclonal antibody therapy is a highly effective and safe method.

According to experts, plasma therapy has shown some promise in treating for the virus, however, inherent problems associated with this approach severely limit its wider use and large scale deployment of this therapy is limited by the availability of the volume of plasma.

Also Read: How Long Will The World Have To Wait For A Vaccine Against COVID-19? Experts Answer


Leave a Reply

Your email address will not be published. Required fields are marked *

Exit mobile version